Cargando…
New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy
Rectal cancer ranks as the second leading cause of cancer-related deaths. Neoadjuvant therapy for rectal cancer patients often results in individuals that respond well to therapy and those that respond poorly, requiring life-altering excision surgery. It is inadequately understood what dictates this...
Autores principales: | Gerber, Scott, Uccello, Taylor, Lesch, Maggie, Kintzel, Sarah, Gradzewicz, Lauren, Lamrous, Lillia, Murphy, Shawn, Fleming, Fergal, Mills, Bradley, Murphy, Joseph, Hughson, Angela, Garrett-Larsen, Jesse, Qiu, Haoming, Drage, Michael, Ye, Jian, Gavras, Nicholas, Keeley, David, Love, Tanzy, Repasky, Elizabeth, Lord, Edith, Linehan, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120761/ https://www.ncbi.nlm.nih.gov/pubmed/37090639 http://dx.doi.org/10.21203/rs.3.rs-2767780/v1 |
Ejemplares similares
-
New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy
por: Uccello, Taylor P., et al.
Publicado: (2023) -
Development of an Orthotopic Murine Model of Rectal Cancer in Conjunction With Targeted Short-Course Radiation Therapy
por: Uccello, Taylor P., et al.
Publicado: (2021) -
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023) -
Cell‐Based Therapies: The Nonresponder
por: Caplan, Arnold I.
Publicado: (2018) -
Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β
por: Bustamante, Marta F., et al.
Publicado: (2015)